This group of subjects will continue to be followed for safety and efficacy for 2 years. Safety will be assessed via incidence of adverse events and evaluation of effect on urologic function and quality of life. Local efficacy will be characterized via MR imaging and evaluated via post treatment prostate-specific antigen (PSA) kinetics including time to PSA nadir and post-nadir PSA stability.